To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide: Phase I data

A Phase I trial in 21 evaluable elderly patients ages 61-77 with previously untreated DLBCL showed that the MTD of Revlimid

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE